Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio"), a privately held, clinical-stage biopharmaceutical company today announced that Dr. Jim Wu, Chief Executive Officer of ArkBio, gave an oral presentation entitled"Development of Next Generation Broadly Active IPF Drug AK3280"at the 8th Annual IPF Summit held in Boston on August 22, 2024. AK3280 is a next-generation broad-spectrum anti-fibrotic drug for the treatment of idiopathic pulmonary fibrosis (IPF) and is undergoing a randomized, double-blind, multicenter phase 2 PoC clinical study. The clinical trial led by Professor Huaping Dai of the China-Japan Friendship Hospital, Beijing, is being conducted across 31 hospitals in China to evaluate the safety, tolerability, and efficacy of AK3280 in IPF patients.

Dr. Wu stated："Although there are already two IPF drugs on the market, both suffer from poor tolerability and lower efficacy that do not improve patient's symptoms. Successful completion of patient enrollment for Phase 2 study is an important milestone for AK3280 as a next generation broadly active IPF drug. We extend our sincere gratitude to all the patients and investigators who participated in the trial for their efforts and contribution. The safety and efficacy results from this study will provide key scientific evidence for the continuous clinical development of the drug. We will work closely with investigators to advance clinical development of AK3280 and address the unmet medical need in treatment of IPF. ArkBio commits to the pursuit of innovative drugs for the treatment of respiratory and pulmonary diseases."